Allergan to Sell Corneal Ulcer Drug

Allergan Inc. said it has received approval from the Food and Drug Administration to market Ocuflox 0.3% for the treatment of corneal ulcers. Allergan said the ophthalmic solution is already indicated for the treatment of bacterial conjunctivitis.

The company, which develops, manufactures and markets specialty therapeutic products for eye and skin care and neuromuscular disorders, licenses Ocuflox from Daiichi Pharmaceutical Co., in Tokyo, and Santen Pharmaceutical Co., in Osaka, Japan.